Successful Rapid Desensitization to Micafungin in a Pediatric Patient
Introduction: Echinocandin antifungal medications including micafungin are being used more commonly in the treatment of invasive fungal infections in both pediatric and adult patients. Micafungin is also a first-line therapeutic option for candidemia and antifungal prophylaxis in a variety of clinical settings. Hypersensitivity reactions have not been well described; however, isolated cases have been reported. No cases of desensitization to echinocandins have been previously described. Case Presentation: In this report, we described a 14-year-old female with high-risk pre-B cell acute lymphoblastic leukemia diagnosed with pulmonary aspergillosis. She developed a hypersensitivity reaction to micafungin, which was deemed first-line therapy for the infection. A rapid intravenous desensitization protocol was successfully completed without reactions. The patient completed the remaining 2 months of therapy without reactions. Conclusion: This report outlines the first report of a successful desensitization to micafungin or any echinocandin. This is a safe method of completing antifungal therapy in a patient with echinocandin hypersensitivity and may be considered for other patients with micafungin hypersensitivities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Pediatric allergy, immunology, and pulmonology - 34(2021), 3 vom: 28. Sept., Seite 106-108 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ward, Stephanie L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 13.01.2022 Date Revised 02.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/ped.2020.1204 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330380389 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330380389 | ||
| 003 | DE-627 | ||
| 005 | 20231225211149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/ped.2020.1204 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM330380389 | ||
| 035 | |a (NLM)34495747 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ward, Stephanie L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful Rapid Desensitization to Micafungin in a Pediatric Patient |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2022 | ||
| 500 | |a Date Revised 02.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: Echinocandin antifungal medications including micafungin are being used more commonly in the treatment of invasive fungal infections in both pediatric and adult patients. Micafungin is also a first-line therapeutic option for candidemia and antifungal prophylaxis in a variety of clinical settings. Hypersensitivity reactions have not been well described; however, isolated cases have been reported. No cases of desensitization to echinocandins have been previously described. Case Presentation: In this report, we described a 14-year-old female with high-risk pre-B cell acute lymphoblastic leukemia diagnosed with pulmonary aspergillosis. She developed a hypersensitivity reaction to micafungin, which was deemed first-line therapy for the infection. A rapid intravenous desensitization protocol was successfully completed without reactions. The patient completed the remaining 2 months of therapy without reactions. Conclusion: This report outlines the first report of a successful desensitization to micafungin or any echinocandin. This is a safe method of completing antifungal therapy in a patient with echinocandin hypersensitivity and may be considered for other patients with micafungin hypersensitivities | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a desensitization | |
| 650 | 4 | |a drug allergy | |
| 650 | 4 | |a hypersensitivity reaction | |
| 650 | 4 | |a micafungin | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Echinocandins |2 NLM | |
| 650 | 7 | |a Micafungin |2 NLM | |
| 650 | 7 | |a R10H71BSWG |2 NLM | |
| 700 | 1 | |a Maciag, Michelle C |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Joyce |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, John |e verfasserin |4 aut | |
| 700 | 1 | |a Broyles, Ana Dioun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric allergy, immunology, and pulmonology |d 2009 |g 34(2021), 3 vom: 28. Sept., Seite 106-108 |w (DE-627)NLM209970928 |x 2151-3228 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2021 |g number:3 |g day:28 |g month:09 |g pages:106-108 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/ped.2020.1204 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2021 |e 3 |b 28 |c 09 |h 106-108 | ||